Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.
- We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.
- The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age.
- The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovias proprietary atropine topical micro-formulation delivered by the Optejet dispenser.
- MicroPine (atropine ophthalmic solution) is Eyenovia's first-in-class topical treatment for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness.